Esperion, Again: Pfizer's First Spin-Out's Familiar Look

This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.

The Pfizer Inc. building in Ann Arbor, Michigan, which housed the former Esperion Therapeutics closed its doors more than a year ago as part of a broad corporate restructuring in the wake of Pfizer’s well-publicized torcetrapib disappointment in late 2006. (See "Best Laid Plans: Pfizer’s Torcetrapib Tanks," IN VIVO, December 2006 Also see "Best Laid Plans: Pfizer's Torcetrapib Tanks" - In Vivo, 1 December, 2006..) But in fact Pfizer’s other efforts in raising HDL were already withering —despite the boost from the late-2003 acquisition of Esperion for $1.3 billion, in large part for that company’s good-cholesterol mimetic Apo A-1 Milano (a.k.a. ETC-216). [See Deal] (See "A Recipe for Acquisition: the Esperion Strategy," IN VIVO, January 2004 Also see "A Recipe for Acquisition: the Esperion Strategy" - In Vivo, 1 January, 2004..) Essentially everything that came into Pfizer via Esperion was either shelved from the outset or quietly discontinued before torcetrapib’s demise "for scientific and technical reasons," according to a spokesperson.

So it shouldn’t be a surprise—now that Pfizer is for the first time actively touting an out-partnering strategy—to see Esperion...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.